about
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particlePneumonias virais: aspectos epidemiológicos, clínicos, fisiopatológicos e tratamentoPandemic influenza: implications for preparation and delivery of critical care servicesFactors Affecting Medical Students' Uptake of the 2009 Pandemic Influenza A (H1N1) VaccineThe 1918 influenza pandemic: lessons for 2009 and the future.Scientific barriers to developing vaccines against avian influenza viruses.Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutininImproving pandemic H5N1 influenza vaccines by combining different vaccine platforms.Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.Modelling control measures to reduce the impact of pandemic influenza among schoolchildren.The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccinesDevelopment of stable influenza vaccine powder formulations: challenges and possibilitiesOne-way trip: influenza virus' adaptation to gallinaceous poultry may limit its pandemic potential.Why is coinfection with influenza virus and bacteria so difficult to control?Development of a vaccine against pandemic influenza viruses: current status and perspectives.Induction of long-term protective immune responses by influenza H5N1 virus-like particles.Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus.Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.Refining the approach to vaccines against influenza A viruses with pandemic potential.Strategies towards universal pandemic influenza vaccines.Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities.Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice.Evaluation of multivalent H2 influenza pandemic vaccines in mice.Pandemic influenza vaccines - the challenges.Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.Pandemism of swine flu and its prospective drug therapy.Vaccination against influenza: role and limitations in pandemic intervention plans.Development of an improved polykaryon-based influenza virus rescue system.High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2).Comparative Safety and Efficacy Profile of a Novel Oil in Water Vaccine Adjuvant Comprising Vitamins A and E and a Catechin in Protective Anti-Influenza Immunity.A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particlesAn open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults.Emerging respiratory viruses: challenges and vaccine strategiesIntegrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics.Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, CanadaZoonotic viral diseases and the frontier of early diagnosis, control and prevention.Epitope specificity of anti-HA2 antibodies induced in humans during influenza infectionKinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination
P2860
Q21562299-3F727F14-6919-418A-8A25-195A8FCEAC74Q22241468-0FA1E79B-0191-495E-A9F7-A7DA76255010Q28390930-373CA1D3-CF28-4E6E-9352-ECB6D9AFD785Q28391795-80A02C1D-BCD0-4617-B6C5-00C3E1FF14D1Q30227352-B248F833-C1F3-4F15-9B8E-CDC9665EE668Q30360468-68C45258-EE16-4523-858A-C05CD3072C11Q30361736-D951E57E-3709-4FEB-A6A1-F430A322374BQ30362811-46700400-85C8-40D7-ADAC-2D863DA36F72Q30363581-2B6208CF-51DF-416A-BEB1-BCC04177ABB3Q30364559-50CFB392-AA26-4BEE-B575-A61372DF618CQ30365696-CF99D108-19D4-491F-8A86-27251865E80FQ30368221-500D5D32-1E7B-4225-B60E-5A6185184CE7Q30370246-220A0815-51AE-46D8-92EF-C66761F17007Q30371269-99CD8214-8118-4A7B-BC43-C8C3D9CB27D2Q30373784-39D3B9C7-A32D-41F1-8426-F8FD89D00833Q30375255-80BFECC3-7E86-4433-96EB-1DC04B9BD1A6Q30376369-140F0FB8-5650-48AF-A13A-40229B788521Q30377224-72BC8419-D4B0-4314-AAE1-FE1C83AD288BQ30377443-AF360A41-9463-423E-949F-6CDC17F4BC8FQ30381595-2EBB7EA7-4013-495C-9FF7-58CE3DC37667Q30382226-7D5F2F18-9454-41FD-922E-E1C51323FDF5Q30382632-BDDB55FD-F65A-453A-9211-02280D29EF28Q30391402-7982D50C-51BC-4E04-8194-11E32DF5731EQ30398507-533E3B6D-1ADB-4FA7-B849-32E245B8F62CQ30408091-87B1806F-7425-4399-9D55-081439A9A888Q30419591-5C1604EC-C263-4088-B518-2E3B88579AE8Q30420391-4F46DD5D-57A8-44B8-9645-54D0DEA07D9FQ30421562-E6B1DD57-4B54-49B4-B186-4DA2DA224AC3Q30533592-F6F559D6-29F1-4896-B181-8288ADEA2C65Q33371468-C0854F8B-3A72-4028-90C3-CF42DE9A62C7Q33749602-7A06639D-D2BC-49A6-AC48-2B39CC91ED17Q34295941-8C679119-365D-42BA-9665-7F176B06B8B4Q34334185-8CDB78D5-5717-41DA-BA05-B1B8961B382EQ35017702-845F178F-565F-4B4E-B903-4DFD56914768Q35070868-1D04DF4E-8378-4967-81B4-4A65E9269B2EQ35139200-E25F4176-AC86-4435-A9FB-AA530318ECBBQ35574565-F79FE6B2-E8A5-49BC-A06F-404E5DC21D4BQ36623106-35422698-7F4D-4F8A-A9BB-B907065F1270Q37087170-AFE8AD9C-5724-4370-A0C9-F2741714C8A5Q37157157-C112BB1F-1C39-4102-8F7E-0F815D51DAC1
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Vaccines for pandemic influenza
@ast
Vaccines for pandemic influenza
@en
type
label
Vaccines for pandemic influenza
@ast
Vaccines for pandemic influenza
@en
prefLabel
Vaccines for pandemic influenza
@ast
Vaccines for pandemic influenza
@en
P2860
P356
P1476
Vaccines for pandemic influenza
@en
P2093
Catherine J Luke
Kanta Subbarao
P2860
P356
10.3201/EID1201.051147
P577
2006-01-01T00:00:00Z